Clinical trial
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary…
NCT00155714 · National Taiwan University Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00155714 |
|---|---|
| Title | Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension |
| Official title | Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension |
| Lead sponsor | National Taiwan University Hospital, Other |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Primary and Secondary Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | type-5 phosphodiesterase Inhibitor (Sildenafil) |
| Enrollment | 20 |
| Start date | Nov 1, 2002 |
| Completion | May 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Mar 16, 2010 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: